Vatsa, Naman Kumar, Vipendra Kumar Singh, Brijesh Kumar, Shashi Shekhar Sharma, Ankit Jana, Nihar Ranjan Table_1_Down-Regulation of miRNA-708 Promotes Aberrant Calcium Signaling by Targeting Neuronatin in a Mouse Model of Angelman Syndrome.XLSX <p>The expression of ubiquitin ligase UBE3A is paternally imprinted in neurons and loss of function of maternally inherited UBE3A causes Angelman syndrome (AS), a neurodevelopmental disorder characterized by severe intellectual disability and motor disturbances. Over activation of UBE3A is also linked with autism. Mice deficient for maternal Ube3a (AS mice) exhibit various behavioral features of AS including cognitive and motor deficits although the underlying molecular mechanism is poorly understood. Here, we investigated possible involvement of miRNA in AS pathogenesis and identified miR-708 as one of the down-regulated miRNA in the brain of AS mice. This miR-708 targets endoplasmic reticulum resident protein neuronatin (a developmentally regulated protein in the brain) leading to decrease in intracellular Ca<sup>2+</sup>. Suppression of miR-708 or ectopic expression of neuronatin increased the level of intracellular Ca<sup>2+</sup> and phosphorylation of CaMKIIα at Thr286. Neuronatin level was significantly increased in various brain regions of AS mice during embryonic and early postnatal days as well as in parvalbumin-positive GABAergic neurons during adulthood with respect to age-matched wild type controls. Differentiated cultured primary cortical neurons obtained from AS mice brain also exhibited higher expression of neuronatin, increased intracellular basal Ca<sup>2+</sup> along with augmented phosphorylation of CaMKIIα at Thr286. These results indicate that miR-708/neuronatin mediated aberrant calcium signaling might be implicated in AS pathogenesis.</p> Angelman syndrome;UBE3A;miR-708;neuronatin;parvalbumin;calcium signaling 2019-02-13
    https://frontiersin.figshare.com/articles/dataset/Table_1_Down-Regulation_of_miRNA-708_Promotes_Aberrant_Calcium_Signaling_by_Targeting_Neuronatin_in_a_Mouse_Model_of_Angelman_Syndrome_XLSX/7712342
10.3389/fnmol.2019.00035.s002